StockData
Vertex Pharmaceuticals Inc logo

Vertex Pharmaceuticals Inc

VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 15/3029% above fair value
$520.66−15.79 (-2.94%)

Close on Nov 19, 2026Market cap $131.97BP/E 30.3Yield –

Vertex Pharmaceuticals KALYDECO (ivacaftor) by Quarter

KALYDECO (ivacaftor) — Net product revenues (standalone through FY2023, $M) ($M)

Vertex Pharmaceuticals KALYDECO (ivacaftor): $112M in Q4 2023, down 17.4% from a year earlier. That is the lowest of the 28 quarters on record here. No newer figure appears in the documents we track.

Latest, Q4 2023
112
Period ended Dec 31, 2023
Change on a year earlier
-17.4%
136 in Q4 2022
History
28 quarters
Since Q1 2017
Sources
23
Documents cited below

Where the Q4 2023 figure comes from

Calculated from reported figures: Q4 = full year (10-K) − nine months (10-Q)

Source: Form 10-K (filed 2024-02-15) ↗

Reported in Form 10-Q / 10-K Revenue Disaggregation Note (combined into Other CF from FY2024).

quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedKALYDECO (ivacaftor) — Net product revenues (standalone through FY2023, $M) ($M)Year on yearSource
Q4 2023Dec 31, 2023112-17.4%Form 10-K (filed 2024-02-15) ↗
Q3 2023Sep 30, 2023113-19.1%Form 10-Q (filed 2023-11-07) ↗
Q2 2023Jun 30, 2023125-9.7%Form 10-Q (filed 2023-08-02) ↗
Q1 2023Mar 31, 2023125-10.1%Form 10-Q (filed 2023-05-02) ↗
Q4 2022Dec 31, 2022136-10.6%Form 10-K (filed 2024-02-15) ↗
Q3 2022Sep 30, 2022139-14.2%Form 10-Q (filed 2023-11-07) ↗
Q2 2022Jun 30, 2022139-24.3%Form 10-Q (filed 2023-08-02) ↗
Q1 2022Mar 31, 2022139-25.4%Form 10-Q (filed 2023-05-02) ↗
Q4 2021Dec 31, 2021152-21.3%Form 10-K (filed 2024-02-15) ↗
Q3 2021Sep 30, 2021162-16.2%Form 10-Q (filed 2022-10-28) ↗
Q2 2021Jun 30, 2021183-9.7%Form 10-Q (filed 2022-08-05) ↗
Q1 2021Mar 31, 2021186-12.4%Form 10-Q (filed 2022-05-06) ↗
Q4 2020Dec 31, 2020193-17.9%Form 10-K (filed 2023-02-10) ↗
Q3 2020Sep 30, 2020194-22.3%Form 10-Q (filed 2021-11-03) ↗
Q2 2020Jun 30, 2020203-22.5%Form 10-Q (filed 2021-07-30) ↗
Q1 2020Mar 31, 2020213-12.9%Form 10-Q (filed 2021-04-30) ↗

Cite this data

StockData. (2026). Vertex Pharmaceuticals KALYDECO (ivacaftor) ($M), quarterly Q1 2017–Q4 2023 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/rev-kalydeco

See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.

See a number that looks wrong?